Mora P, Chapouly C
Front Immunol. 2023; 14:1254586.
PMID: 37936690
PMC: 10627009.
DOI: 10.3389/fimmu.2023.1254586.
Shimizu D, Kanda M, Kodera Y
World J Gastrointest Oncol. 2018; 10(6):124-136.
PMID: 29988904
PMC: 6033711.
DOI: 10.4251/wjgo.v10.i6.124.
Chapouly C, Argaw A, Horng S, Castro K, Zhang J, Asp L
Brain. 2015; 138(Pt 6):1548-67.
PMID: 25805644
PMC: 4614128.
DOI: 10.1093/brain/awv077.
Ogawa M, Watanabe M, Mitsuyama Y, Anan T, Ohkuma M, Kobayashi T
Oncol Lett. 2014; 8(6):2463-2468.
PMID: 25364408
PMC: 4214505.
DOI: 10.3892/ol.2014.2574.
Maw M, Fujimoto J, Tamaya T
Exp Ther Med. 2012; 1(2):351-356.
PMID: 22993548
PMC: 3445945.
DOI: 10.3892/etm_00000055.
Angiogenesis and lymphangiogenesis of gastric cancer.
Kitadai Y
J Oncol. 2010; 2010:468725.
PMID: 20369064
PMC: 2847386.
DOI: 10.1155/2010/468725.
Cancer-stromal cell interaction and tumor angiogenesis in gastric cancer.
Kitadai Y
Cancer Microenviron. 2009; 3(1):109-16.
PMID: 20020278
PMC: 2970808.
DOI: 10.1007/s12307-009-0032-9.
Overexpression of inhibitor of DNA-binding (ID)-1 protein related to angiogenesis in tumor advancement of ovarian cancers.
Maw M, Fujimoto J, Tamaya T
BMC Cancer. 2009; 9:430.
PMID: 20003244
PMC: 2796680.
DOI: 10.1186/1471-2407-9-430.
Thymidylate synthase, thymidine phosphorylase, VEGF and p53 protein expression in primary colorectal cancer for predicting response to 5-fluorouracil-based chemotherapy.
Ahn M, Choi J, Oh H, Lee Y, Kim I, Choi I
Cancer Res Treat. 2009; 37(4):216-22.
PMID: 19956517
PMC: 2785918.
DOI: 10.4143/crt.2005.37.4.216.
The dual role of thymidine phosphorylase in cancer development and chemotherapy.
Bronckaers A, Gago F, Balzarini J, Liekens S
Med Res Rev. 2009; 29(6):903-53.
PMID: 19434693
PMC: 7168469.
DOI: 10.1002/med.20159.
Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival.
Kim J, Kim M, Kim T, Lee S, Kim D, Im S
Br J Cancer. 2009; 100(5):732-8.
PMID: 19259093
PMC: 2653762.
DOI: 10.1038/sj.bjc.6604936.
Expression of the inhibitor of DNA-binding (ID)-1 protein as an angiogenic mediator in tumour advancement of uterine cervical cancers.
Maw M, Fujimoto J, Tamaya T
Br J Cancer. 2008; 99(10):1557-63.
PMID: 19002177
PMC: 2584935.
DOI: 10.1038/sj.bjc.6604722.
The cytosol activity of thymidine phosphorylase in endometrial cancer.
Miszczak-Zaborska E, Kubiak R, Bienkiewicz A, Bartkowiak J
J Exp Clin Cancer Res. 2008; 27:64.
PMID: 18986516
PMC: 2588563.
DOI: 10.1186/1756-9966-27-64.
Expression of IP-10 related to angiogenesis in uterine cervical cancers.
Sato E, Fujimoto J, Toyoki H, Sakaguchi H, Alam S, Jahan I
Br J Cancer. 2007; 96(11):1735-9.
PMID: 17505511
PMC: 2359925.
DOI: 10.1038/sj.bjc.6603790.
A possible role of thymidine phosphorylase expression and 5-fluorouracil increased sensitivity in oropharyngeal cancer patients.
Ranieri G, Grammatica L, Patruno R, Zito A, Valerio P, Iacobellis S
J Cell Mol Med. 2007; 11(2):362-8.
PMID: 17378915
PMC: 3822834.
DOI: 10.1111/j.1582-4934.2007.00007.x.
Plausible linkage of hypoxia inducible factor-1alpha in uterine cervical cancer.
Fujimoto J, Alam S, Jahan I, Sato E, Toyoki H, Hong B
Cancer Sci. 2006; 97(9):861-7.
PMID: 16805819
PMC: 11158725.
DOI: 10.1111/j.1349-7006.2006.00262.x.
Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer.
Toi M, Bando H, Horiguchi S, Takada M, Kataoka A, Ueno T
Br J Cancer. 2004; 90(12):2338-43.
PMID: 15150550
PMC: 2409525.
DOI: 10.1038/sj.bjc.6601845.
Clinical implications of expression of ETS-1 in relation to angiogenesis in ovarian cancers.
Khatun S, Fujimoto J, Toyoki H, Tamaya T
Cancer Sci. 2003; 94(9):769-73.
PMID: 12967474
PMC: 11160155.
DOI: 10.1111/j.1349-7006.2003.tb01517.x.
Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches.
Poon R, Fan S, Wong J
Ann Surg. 2003; 238(1):9-28.
PMID: 12832961
PMC: 1422670.
DOI: 10.1097/01.sla.0000075047.47175.35.
Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.
Terashima M, Fujiwara H, Takagane A, Abe K, Irinoda T, Nakaya T
Gastric Cancer. 2003; 6 Suppl 1:71-81.
PMID: 12775024
DOI: 10.1007/s10120-003-0221-z.